William Jeffery Edenfield, MD
Fax: (864) 404-2011
About us
Jeff Edenfield, MD, is a hematology/oncology physician and the Executive Medical Director of Oncology for the Prisma Health Cancer Institute in Greenville, South Carolina. He currently serves as medical director for the Institute for Translational Oncology Research, which includes conduct and oversight of phase I and first-in-human clinical trials for new cancer medications as well as management of the biorepository services at Prisma Health Cancer Institute.
Dr. Edenfield received his medical degree from the University of Miami in Florida, and completed his internship, residency and fellowship at Walter Reed Army Medical Center in Washington, DC. He completed a research fellowship in hematologic malignancy at Johns Hopkins University School of Medicine in Baltimore, Maryland. He completed his active-duty service obligation as chief of oncology at Womack Army Medical Center in North Carolina.
Dr. Edenfield is board certified in medical oncology, hematology, internal medicine and hospice and palliative medicine.
| Tags | breast cancer immunotherapy, adamantinoma, adjuvant chemotherapy, adult stem cell collection for transplant, adverse effects to anticoagulants, alveolar soft part sarcoma, amyloidosis, anaplastic cancer of thyroid, anemia, anemia of chronic disease, anemia of pregnancy, antithrombin deficiency, aplastic anemia, b12 deficiency anemia, biological targeted therapy, bladder cancer genomics, bleeding disorder, blood cancer, blood disorders, bone marrow disorders, bone sarcoma, brain cancer genomics, breast cancer genetics, cancer, cancer chemotherapy, cancer during pregnancy, cancer genomics, cancer pain, cancer rehabilitation, cancer survivor, cancer related fatigue, cardio oncology, castleman's disease, cervical cancer genomics, cervical teratoma, chemoradiation, colon cancer genomics, cooley anemia, cowden syndrome, cryoglobulinemia, diamond blackfan anemia, diffuse intrinsic pontine glioma (dipg), early detection of cancer, purpura, radionuclide therapy, rectal cancer genomics, reduced intensity conditioning regimens, renal cancer genomics, retroperitoneal mass, rh incompatibility, sacrococcygeal teratoma, sarcoma genomics, secondary polycythemia, side effects of cancer treatment, skin cancer genomics, splenomegaly, stomach cancer, stomach cancer genomics, submucosal tumors, sweat gland carcinoma, tectal glioma, thalassemia, thrombocytopenia, thrombocytosis, thrombophilia, thyroid cancer genomics, endocrine complications of cancer therapy, endometrial cancer, endometrial cancer genomics, epithelioid hemangioendothelioma, factor v leiden, familial aplastic anemia, fanconi anemia, fibrosarcoma of the head & neck, follicular cancer of thyroid, gallbladder cancer genomics, gastrointestinal (gi) cancer genomics, genitourinary cancer genomics, giant cell tumor of the bone, glucose 6 phosphate dehydrogenase deficiency, head and neck cancer, head and neck cancer genomics, hellp syndrome, hemochromatosis, hemoglobinopathies, hemolytic anemia, hemolytic uremic syndrome, heparin induced thrombocytopenia, hereditary cancer risk, hereditary spherocytosis, histiocytosis, hypogammaglobulinemia, idiopathic thrombocytopenic purpura, cancer immunotherapy, iron deficiency anemia, langerhans cell histiocytosis, leukemia genomics, leukopenia, li fraumeni syndrome, liver cancer genomics |